-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The sodium sodium intestinal tablet is a third-generation type of proton pump inhibitor, mainly used to treat duodenal ulcers, stomach ulcers, moderate and severe reflux esophagitis, with kramycin and amoxicillin, or kramycin and metformin, or amoxicillin and methazine can be used to eradicate Helicobacter pylori infection.
was first developed by Byd Gulden in Germany and first listed in Germany in 1994, with a product called Pantoloc ®.
China has been successfully imitation in 1998, and has approved the raw materials of sodium cesiumazole, intestinal tablets, intestinal lysis, injections and other dosage forms on the market.
-meter-net terminal data show that the corresponding retail and medical end market in 2019 the sales of oral preparations of etoprazole is about 2.5 billion yuan.
According to the data of the PDB Comprehensive Drug Database of the China Pharmaceutical Industry Information Center, in 2019 the company has a small market share and a large rheumatoid space in the statistical samples of 22 key urban hospitals in China.
as of the announcement day, Nine Pharma for the domestic two through the protoprazole sodium intestinal tablet consistency evaluation of enterprises.
.